Amanda is Executive Director (ED) and global lead for Search and Evaluation, Obesity and General Medicines, on Amgen’s Business Development team. In this role, she is responsible for opportunity identification, technical due diligence, and supporting deal execution across all asset stages and modalities. Amanda has been at Amgen for over six years, holding roles of increasing responsibility. In her last role, she was ED Global Marketing and Disease Area Strategy Lead for the Inflammation therapeutic area (TA), responsible for leading the TA strategy and serving as the Commercial lead for five Inflammation pipeline programs. She also served as product team lead for two programs. Previously, Amanda served as Director, Business Development (External R&D), Inflammation TA, where she served as the BD representative on the Inflammation TA Governance and had leadership roles in multiple BD deals: Amgen’s collaboration with Kyowa Kirin and the acquisitions of Rodeo, Chemocentryx, and Horizon. When she first joined Amgen, she led External R&D for the Cardiometabolic TA. Prior to joining Amgen in 2019, Amanda worked at the University of Southern California where she co-founded a new team responsible for early technology evaluation and biotech entrepreneurship. Previously, Amanda worked at Bain as a management consultant focusing on business development and strategy for biopharma clients. Amanda has a PhD in Developmental and Stem Cell Biology from the University of California San Francisco and an AB in Molecular and Cellular Biology from Harvard University, where she graduated summa cum laude. In her free time, she is an avid scuba diver and ceramic artist.